Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4277194 | Urology Practice | 2014 | 5 Pages |
Abstract
Surveillance is the most cost-effective management strategy for clinical stage I seminoma during the first 5 years of treatment. Although not evaluated in this analysis, costs of late side effects associated with radiotherapy and chemotherapy should be considered. Due to potentially minimal late side effects and superior cost-effectiveness, surveillance represents a safe, cost-effective and time effective option for the management of stage I seminoma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Khanh N. Pham, Richard B. Johnston, Claudio Jeldres, Craig R. Nichols, Christopher R. Porter,